We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Tara
Evans
tara.evans@nhs.net
Massimiliano
Di Pietro
md460@cam.ac.uk
Massimiliano
Di Pietro
md460@cam.ac.uk
Malignant neoplasms of digestive organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Cancers of the upper gastro-intestinal (GI) tract (oesophagus/gullet, stomach and small bowel) are amongst the deadliest malignancies. The main reason for their high mortality is that they are usually identified late when they are at a non-curable stage. However, a significant volume of research has confirmed that these tumours develop from known recognisable pre-cancerous lesions. This provides an opportunity for clinicians to detect these pre-cancerous areas early and treat them before they progress to cancer. A camera test (endoscopy) is the gold-standard test to detect diseases in these organs. However, there has been limited research to set the standards of the procedure’s performance especially with regards to diagnostic ability of the physician performing the procedure. As such, the aforementioned pre-cancerous lesions are understudied and often go undetected given that it is difficult to find them.
This study aims to understand how often we should be identifying these pre-cancerous lesions on routine endoscopy and investigate to set the standards to measure performance in upper GI endoscopy. We will also assess how often clinicians are correct in detecting pre-cancerous lesions on endoscopy, by comparing the endoscopic findings to the microscope test (histological) results from tissue samples biopsies taken during the procedure. In addition, we will compare expert to less experienced endoscopists in their ability to identify these precancerous lesions. Finally, we will assess whether the time spent to look with the camera inside food pipe stomach and small bowel affects the rate of correct diagnosis.
By evaluating these aspects, we expect to enhance our understanding about key aspects of the diagnosis of these pre-cancerous lesions. In turn we aim to set endoscopy standards to improve their early detection and removal before they progress to cancer with major benefit to patients.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cross-sectional;
You can take part if:
You may not be able to take part if:
1) Known high-risk lesions or premalignant conditions under endoscopic monitoring (such as gastric ulcers, Barrett’s oesophagus, oesophageal dysplasia, duodenal or gastric polyps, upper GI malignancy) 2) Previous oesophagectomy or gastrectomy for malignant disease 3) OGD performed within previous 3 years prior to the study 4) Coagulopathy or anticoagulant/antiplatelet therapy for high risk conditions whereby the patient is unable to discontinue the medication
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Massimiliano
Di Pietro
md460@cam.ac.uk
Massimiliano
Di Pietro
md460@cam.ac.uk
Tara
Evans
tara.evans@nhs.net
The study is sponsored by CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST and funded by BRITISH MEDICAL ASSOCIATION SCHOLARSHIP TRUST FUND .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 49853
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
